Kornimate/medical-research-clean huggingface dataset:
screening to prophylax against clostridium difficile infection -

Conditions: Clostridium Difficile Infection

Summary: the goal of this study is to evaluate whether using vancomycin orally can prevent cdi in patients who are colonized with c. difficile who are admitted to the hospital and need antibiotics for another infection.

screening to prophylax against cdi (stop cdi) is a prospective, single-center, double-blinded, randomized, placebo-controlled study of the effectiveness of vancomycin vs. placebo for preventing cdi in patients colonized with toxigenic c. difficile and receiving high-risk antibiotics. the investigators plan to screen 2500 patients to randomize 200. consented patients will have a stool sample collected and tested for presence of toxigenic c. difficile by polymerase chain reaction (pcr) test. patients who test negative will simply be followed for development, severity and outcome of cdi. patients who test positive (are colonized with c. difficile) will be randomized to one of two arms: arm 1: patients receive 125 mg vancomycin by mouth (po) every 6 hours as prophylaxis against c. difficile for the duration of their antibiotic treatment +3 days. arm 2: patients receive placebo by mouth (po) every 6 hours for the duration of their antibiotic treatment +3 days.

Eligibility criteria:
inclusion criteria: 1. expected duration of admission sufficient to complete screening and enrollment 2. age ≥18 3. able to give informed consent 4. initiated on one of the following antibiotics within the prior 72 hours with an expected duration of at least 72 hours from enrollment: clindamycin, ampicillin, ampicillin/sulbactam, amoxicillin, amoxicillin/clavulanate, moxifloxacin, levofloxacin, piperacillin/tazobactam, or any cephalosporin 5. maximum expected duration of antibiotics 8 weeks 6. able to take oral study medications 7. able to provide a stool sample during hospitalization or within 3 days of discharge 8. reasonably expected to be able to complete follow up exclusion criteria: 1. chron's disease, ulcerative colitis, celiac disease, or other chronic diarrheal illness 2. cdi within prior 90 days 3. currently on metronidazole, oral vancomycin, rifaximin, fidaxomicin, or any other antibiotic active against c. difficile 4. current diarrhea 5. current ileostomy, colostomy or other form of surgically disconnected gut such that oral therapy would not be expected to reach the entire lumen of the gut 6. pregnancy or breast feeding (determined prior to randomization) 7. travel to an area of endemic diarrheal illness within the last 30 days 8. life expectancy of less than 60 days 9. known allergy to vancomycin 10. participation with other research trials that could impact the results of this trial within the last 30 days 11. previously enrolled in this study
new daily persistent headache biomarkers study

Conditions: New Daily Persistent Headache; New Daily Persistent Headache (NDPH)

Summary: new daily persistent headache is a debilitating syndrome which is seldom researched, poorly understood, and without effective treatments. chronic migraine is a more common but similarly disabling disorder. the goal of this study is to evaluate the blood levels of two proteins involved with pain signaling; calcitonin gene-related peptide (cgrp) and nerve growth factor (ngf). cgrp levels are known to be elevated in chronic migraine, and recent phase 2 clinical trials suggest that treatments targeting cgrp are safe and effective for treatments for migraine. if cgrp levels are elevated in the blood of people with new daily persistent headache, future studies will be designed to evaluate whether treatments that target cgrp are effective in treating new daily persistent headache. if ngf levels are elevated in the blood of patients with new daily persistent headache and/or chronic migraine, future studies will be designed to evaluate whether treatments that target ngf antibodies (targeted treatments against ngf) are effective in treating ndph and/or chronic migraine.


Eligibility criteria:
inclusion criteria: * to add exclusion criteria: * to add

Keywords: headache
ultrasound evaluation of remission in rheumatoid arthritis

Conditions: Rheumatoid Arthritis Patient With Remission :Ultrasonographic Disease Activity

Summary: evaluate correlations between the validated 12 joints-naredo ultrasound score (b-mode (0-3), pd (0-3) or pdus (0-3, max between b-mode or pd)) and the das28-esr, das28-crp, cdai, sdai and acr-eular criteria for remission in routine care.

clinical remission is now a realistic goal in managing rheumatoid arthritis (ra) with treat to target strategy assessed according to different composite scores (das28, simplified disease activity index (sdai), clinical disease activity index (cdai), acr-eular 2011 for remission). there are, however, no validated ultrasound remission criteria because of continuing uncertainty on the signification of persistent synovial hypertrophy in b-mode or power doppler (pd) mode in ra patients in clinical remission. the objective was to evaluate correlations between the validated 12 joints-naredo ultrasound score (b-mode (0-3), pd (0-3) or pdus (0-3, max between b-mode or pd)) and the das28-esr, das28-crp, cdai, sdai and acr-eular criteria for remission in routine care. this french multicenter cross-sectional study took place in 11 rheumatology departments. the inter and intra-observer reproducibility for the ultrasound scoring was good to excellent. inclusion criteria were as follows: ra meeting acr-eular criteria, \<15 years of progression, das-28-esr\<2.6 for at least 3 months, with a stable treatment including corticoids if necessary (equivalent prednisone\<0.1 mg/kg) for 6 months. a standardized us examination was performed by an experience ultrasonographist blinded to clinical data. spearman's correlation coefficients were determined between the naredo12 b-mode (min-max,0-36), pd mode (0-36) and pdus (0-36) scores and the different clinical remission scores. the impact of disease duration or duration of the clinical remission on ultrasound scores was also assessed (kruskall-wallis's test).

Eligibility criteria:
inclusion criteria: * adults (âged of 18 or more), * rheumatoid arthritis according to acr-eular 2010 criteria, during less than 10 years at least * remission according to das28-vs (\<2.6) since 3 months at least, * disease modifying anti-rheumatic drugs and/or biotherapy stable dose since 6 months at least * steroids ≤0.1 mg/kg/day without high dose during the last 3 months * oral and written information and consent exclusion criteria: * patient participating to a clinical trial about rheumatoid arthritis treatment * patient under administrative supervision

Keywords: rheumatoid arthritis, remission, ultrasound
patterns of urinary bladder cancer in darfur, suda

Conditions: Urinary Bladder Cancer

Summary: background: bladder cancer (bc) exhibits extreme heterogeneity regarding clinical outcome, etiology, histology, and geographic distribution. recent clinical observations point to alterations in the bc pattern in the sudan, possibly as a result of lifestyle changes brought on by the enormous migration from rural to urban locations. this study aimed to identify the pattern of bladder cancer in darfur. patients and methods: a cross sectional, hospital-based study, it was conducted innyala specialized hospital, during the period from (2020 to 2022), included one hundred and five patients with bladder mass matching the inclusion criteria were studied over the diversity of demographic data , clinical finding, pathological type and possible risk factors .


Eligibility criteria:
inclusion criteria: * all sudanese pts who lives in darfur and presented with urinary bladder mass. * adult above 18 years exclusion criteria: * patient who does not live in darfur. * patients refused to participate in the study.
a trial to evaluate the precision and accuracy of the nbm-200 series when used in a continuous prospective mode

Conditions: Anemia

Summary: the purpose of the study is to define the precision, accuracy and variability of the nbm-200 system in non invasive blood hemoglobin (hb) measurements relative to the laboratory blood analyzer by comparing two consecutive hb values obtained by the nbm system to venous values.

each subject will be placed in a comfortable position in a temperature regulated room. participants will have two consecutive non invasive (nbm) measurements taken which involves inserting the thumb into a ring shaped sensor. after each non invasive measurement the sensor will be removed. each measurement takes approximately 85 seconds and involves the finger cuff inflating (to over systolic pressure) and deflating several times in quick successions in order to measure and calculate the hb values. the two non invasive measurements will be performed using the same finger. after the nbm system testing is complete and recorded, the subject will have a venous (venipuncture) blood sample collected in order to provide two blood tests performed on two different models of routine automated complete blood count or hb blood analyzers. addendum: reproducibility procedure (optional) each subject will be measured by each one of the three operators, three nbm system units, 3 times consecutively (without removal) on his right thumb and right index finger. the order of each measurement sequence will be randomized (thumb/index). there will be an intermission of 3 to 5 minutes between the 3 measurement sets taken on each participant. in case of a longer intermission, the subject will be measured again and the previous results will be excluded.

Eligibility criteria:
inclusion criteria: * aged 18 years and over * healthy volunteers * anemia patients exclusion criteria: * participants under the age of 18 years * patients with significant deformity, degenerative changes or oedema of the thumb or index fingers * patients with localized infection, ulceration or skin breaks involving the fingers * patients with vascular disease or raynaud's phenomenon affecting the fingers * participants who are unable to give informed written consent * pregnancy
telenursing and transitional care

Conditions: Lumbar Disc Surgery

Summary: post-operative care for lumbar disc herniation (ldh) is important to reduce postoperative complications. the transition from hospital to home after discharge is important for ldh patients, as the transition process is flawless, the necessary care is provided appropriately, and follow-up is important. the aim of the study is to determine the effects of transitional model-based telenursing and mobile application-based follow-up on fall risk, post-discharge recovery, mobility, anxiety, and complications in patients who underwent lumbar disc surgery.


Eligibility criteria:
inclusion criteria: * patients who are 18 years of age or older, * can speak and understand turkish, * have no hearing, understanding, vision or speech problems, * have undergone ldh surgery for the first time, * have undergone ldh surgery with the open method, * have not been diagnosed with depression or anxiety disorder before surgery and are not taking medication for this purpose, * have a smart mobile phone suitable for taking photos or for those close to them, * have not developed serious complications that would delay their discharge from the hospital, * volunteer to participate in the study will be included in the study. exclusion criteria: * patients who wish to withdraw from the study at any stage after voluntarily participating in the study.

Keywords: mhealth telenursing transitional care lumbar disc surgery complications
exploratory study on her2 detection method and positive threshold for high-grade serous adenocarcinoma of the ovary

Conditions: Exploring HER2 Positive Diagnostic Criteria in High-grade Serous Ovarian Cancer; Observing the Effectiveness of Targeted HER2 ADC Drugs

Summary: ovarian cancer is the most lethal gynecological malignancy, and 70% of ovarian cancer patients are diagnosed late at the time of new diagnosis. even after systematic treatment, 75% of patients still relapse within 3 years and 70% die within 5 years. the survival prognosis of platinum resistant and refractory ovarian cancer populations is currently an urgent issue that needs attention. antibody drug conjugate (adc) targeting human epidermal growth factor receptor 2 (her2) significantly improved the survival prognosis of patients with multiple solid tumors, such as breast cancer, gastric cancer, colorectal cancer, etc. anti her2 drugs have been a research hotspot in the treatment of advanced ovarian cancer in recent years. the expression status of her2 has a decisive impact on the efficacy of adc drugs targeting her2. however, there is still a lack of large-scale data on her2 expression rate in ovarian cancer patients, and there is no clear detection standard to guide clinical practice, which restricts the application of anti-her2 adc drugs in ovarian cancer. to address this critical clinical issue, we initiated this study, which was divided into two parts: ① retrospective study: using the existing 144 samples of high-grade serous epithelial ovarian cancer(hgsoc) in our center, we used immunohistochemistry (ihc), dna in situ hybridization (ish), and second-generation sequencing (ngs) techniques to detect her2 status, clarify the relationship between her2 expression rate and patient survival outcomes, and preliminarily explore the best detection techniques and corresponding positive judgment thresholds for evaluating her2 status in hgsoc; ② real world observational study: to verify the predictive value of the positive judgment threshold determined in ① for efficacy in 20 ovarian cancer patients who received her2 targeted adc drugs due to platinum resistance/platinum refractory and no other effective treatment options in clinical practice. the aim of this project is to explore for the first time a reliable and feasible method for assessing the expression status of her2 in patients with epithelial ovarian cancer, in order to provide a basis for subsequent evaluation of targeted her2 therapy.


Eligibility criteria:
inclusion criteria: 1. pathological type: high-grade serous adenocarcinoma of the ovary 2. pathological slices stored within 5 years 3. figo stage ii or above 4. complete clinical and follow-up data exclusion criteria: 1. slice quality control failure 2. incomplete follow-up data
pain perception after tubal ligation

Conditions: Pain

Summary: the purpose of this study is to attempt to determine retrospectively whether there was a statistically significant difference in patient need for postoperative narcotics between two different groups of women who received a laparoscopic tubal ligation. one group received a local anesthetic injection or gel at the surgical sites, in addition to general anesthesia. the other group did not receive any local anesthetic but did receive general anesthesia. the investigators hypothesize that the group that received the local anesthetic injection or gel had lower average postoperative narcotic requirements and shorter postoperative dismissal to home times than the group that did not receive the auxiliary local anesthetic.


Eligibility criteria:
inclusion criteria: * female, age 21-52,having a laparoscopic tubal ligation by the fallopia ring method at oklahoma state university medical center between january 1, 2005 and december 31, 2009 exclusion criteria: * we will exclude women with the following comorbid conditions, since they may alter the patient's pain level or her perception of pain after the tubal ligation: history of chronic pelvic pain, history of pelvic inflammatory disease, opiate abuse, conversion to open procedure, unsuccessful tubal ligation, laceration of tube, more than one ring placed on single tube, admittance to the hospital, additional procedures performed, endometriosis, allergy to marcaine, lidocaine, or bupivicaine.

Keywords: postoperative pain tubal ligation local anesthetic
aortic or mitral valve replacement with the biocor and biocor supra

Conditions: Aortic Valve Insufficiency; Aortic Valve Regurgitation; Aortic Valve Stenosis; Aortic Valve Incompetence; Mitral Valve Insufficiency; Mitral Valve Regurgitation; Mitral Valve Stenosis; Mitral Valve Incompetence

Summary: the purpose of this study is to further evaluate the long-term safety and effectiveness of the biocor and biocor supra valves.

the clinical investigation is a multi-center, prospective, non-randomized, observational, fda-required post-approval study designed to further evaluate the safety and effectiveness of the biocor and biocor supra valves.

Eligibility criteria:
inclusion criteria: * requires aortic or mitral valve replacement (heart surgery such as bypass is allowed at the same time) * legal age * signed informed consent prior to surgery * willing to complete all follow-up requirements exclusion criteria: * pregnant or nursing women * already have had a valve replaced other than that for the scheduled replacement * needs another valve replaced * cannot return for required follow-up visits * have active endocarditis * acute preoperative neurological event (such as a stroke) * renal dialysis * history of substance abuse within one year or is a prison inmate * participating in another study * had the biocor or biocor supra valve implanted but then the device was explanted * life expectancy less than five years

Keywords: aortic valve mitral valve heart valve tissue valve bioprosthesis valve disorder valve disease cardiac surgery aortic valve regurgitation aortic valve stenosis mitral valve regurgitation mitral valve stenosis
epidemiological study in hypertensive patients: assessment of risk factors prevalence and of patients' management

Conditions: Hypertension

Summary: to assess the pattern of hypertension in the population in terms of presence of additional risk factors (arf) and cardiovascular risk stratification.

routine physician visits

Eligibility criteria:
inclusion criteria: * age 18 to 80 years old * patients with hypertension: newly diagnosed and /or already diagnosed and treated , whether at goal or not for the blood pressure level; * patients with no history of chd/cvd exclusion criteria: * none

Keywords: epidemiology, hypertension, risk factors, coronary heart disease, patient management, compliance with medication
study on pazopanib when given with folfox6 (fluorouracil, oxaliplatin, leucovorin) or capeox (capecitabine, oxaliplatin)

Conditions: Neoplasms, Colorectal

Summary: this study will test the safety of treating colorectal cancer with a combination of drugs. the current standard treatments of folfox6 or capeox will be give in combination with the gsk investigational drug pazopanib.


Eligibility criteria:
inclusion criteria: * diagnosis of locally advanced or metastatic colorectal cancer. * no prior chemotherapy for metastatic disease. * presence of radiologically and/or clinically documented disease. * eastern cooperative oncology group performance status of 0 or 1. * adequate bone marrow, hepatic, renal function, urine creatinine ratio (upc) of \< * a female subject must not be pregnant or breast feeding. * able to swallow and retain oral medications. exclusion criteria: * has had any major surgery, chemotherapy, hormone therapy, investigational agent, or radiotherapy within the last 28 days * prior treatment with pazopanib, or oxaliplatin. * known contraindications to the use of oxaliplatin, capecitabine, 5-fluorouracil, or folinic acid. * participation in any investigational study within 28 days prior to study treatment. * women who are pregnant or lactating. * poorly controlled hypertension. * a history of cardiovascular disease, arrhythmias, or significant ecg abnormalities. * any history of stroke. * current use of therapeutic warfarin. * known brain metastases. * history of disease significantly affecting gastrointestinal function or major resection of the stomach or small bowel. * active infections or other serious illness. * history of allergy to platinum compounds or heparin. * poor venous access.

Keywords: pharmacokinetics colorectal cancer pazopanib capecitabine capeox 5-fluorouracil oxaliplatin combination therapy folfox 6
high volume injection or autologous conditioned plasma (acp) in chronic achilles tendinopathy

Conditions: Tendinopathy

Summary: the aim of the study is to examine patients with chronic achilles tendinopathy (at) and to compare the effect of high volume injection (hvi) or autologous conditioned plasma (acp) in combination with eccentric training to placebo treatment (sham treatment combined with eccentric exercises). healthy males with at will be randomly assigned to either 1) hvi (50 mls;10 mls 0.5% bupivacaine hydrochloride and 20 mg of depomedrol followed by 40 mls saline), 2) acp (\~ 4 mls) or 3) placebo (plc) treatment. all subjects will perform a 12-wk eccentric training program and examinations will be done at baseline (before treatment) with follow-ups after 6 weeks, 12 weeks and again after 24 weeks prior to baseline to see any possible changes and differences between groups (hvi, acp and plc)

chronic achilles tendinopathy (at) is a common and impairing disorder. only sparse scientific evidence exists for the present used treatments and no golden standard treatment exists so far. aim: the aim of the study is in at patients to examine and compare the effect of high volume injection (hvi) or autologous conditioned plasma (acp) in combination with eccentric training to placebo treatment (sham treatment and eccentric exercises). materials and methods: healthy males (21-59 years; n=60) with at is randomly assigned to either 1) hvi (50 mls;10 mls 0.5% bupivacaine hydrochloride and 20 mg of depomedrol followed by 40 mls saline), 2) acp (\~ 4 mls) or 3) placebo (plc) treatment. participants will treated on 4 successive occasions with 2 weeks (wks) interval (hvi will only be injected once at baseline, the 3 following injections will be placebo). the injections will be performed under ultrasound guidance. all subjects will undergo a 12-wk eccentric training program. clinical effects will be assessed as changes in symptoms and pain (visa-a and vas score), tendon ultrasound thickness and muscle function (one-legged heel-rise test). all outcome measures will be recorded at baseline and again at 6 weeks, 12 week and 6 month follow-up. results: will se the changes and differences between groups (hvi, acp and placebo) in visa-a scores, vas scores, ultrasound (tendon thickness) and muscle function. statistics: all data will be analyzed in sigmaplot v11 using two-way repeated measures anova with student-newman-keuls post-hoc test. this is used to see changes over time in all groups (time effect) and differences between groups within time-points (group effect). all data will be presented as mean ± sem time.

Eligibility criteria:
inclusion criteria: * clinically and ultrasound diagnosed unilateral midt-tendinous achilles tendinopathy * symptoms \> 3 month * no steroid injections \< 6 month * 60 males with bmi \<30 between 18-60 years. exclusion criteria: * bilateral achilles tendinopathy * insertional tendinopathy * steroid injections \< 6 month * diabetes or cardiovascular disease * smoking * treatment with fluoroquinolones \< 6 month